Roctavian Withdrawn, Exposing Science‑to‑market Gap
Failing to find a buyer, BioMarin is voluntarily withdrawing Roctavian from the market. A fitting end for what was once one of the highest-profile gene therapies in development — and a reminder of the gap between promising science and a viable drug: https://t.co/wl5EFH3fpD
Budapest’s Turbine Secures $25M to Simulate Lab Experiments
The latest AI biotech raise comes not from the Bay Area or Boston, but out of Budapest Turbine has closed a $25M Series B, planning to build AI models that can simulate more and more lab experiments: https://t.co/Q31DVENA9G
IPO Priced at $15‑$17, Valuing Firm at $2 B
Generate estimated it would price its shares at $15 to $17 apiece, translating to a valuation ranging from $1.91 billion to $2.17 billion — not counting an underwriter's option: https://t.co/n9nJsbJuvm
Terray's Non‑diffusion AI Beats Boltz
NEW: Terray has taken a contrarian AI approach, building a non-diffusion-based model for binding affinity predictions They shared some H2H results against Boltz-2, a popular open-source model, showing 20% more accuracy + 26x faster to run: https://t.co/BFZU8y6qI8
AI Models May Cheat on Molecular Binding Predictions
The Utah-based startup Leash Bio is warning of the potential for AI models to be cheating on tasks like predicting binding affinities of molecules I talked with @allmeasures about how its "Name that Chemist" quiz relates to the goal of generalization:...
